Exploring 3 High Growth Tech Stocks in South Korea

The South Korea stock market on Wednesday ended a three-day slide, with the KOSPI barely higher at 2,689.83 amid mixed global forecasts and key inflation data ahead. In this fluctuating environment, identifying high-growth tech stocks that can navigate both gains and losses becomes crucial for investors looking to capitalize on South Korea's dynamic tech sector.

Top 10 High Growth Tech Companies In South Korea

Name	Revenue Growth	Earnings Growth	Growth Rating
Seojin SystemLtd	33.61%	52.05%	★★★★★★
IMLtd	20.76%	106.30%	★★★★★★
Bioneer	23.53%	97.58%	★★★★★★
FLITTO	32.07%	100.38%	★★★★★★
ALTEOGEN	64.22%	99.46%	★★★★★★
NEXON Games	31.70%	66.31%	★★★★★★
Devsisters	26.11%	65.92%	★★★★★★
AmosenseLtd	24.29%	55.45%	★★★★★★
Park Systems	23.49%	35.59%	★★★★★★
UTI	103.56%	122.67%	★★★★★★

Click here to see the full list of 52 stocks from our KRX High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩16.95 billion.

Operations: ALTEOGEN Inc. generates revenue primarily from its biotechnology segment, amounting to ₩90.79 million. The company focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.

ALTEOGEN's revenue is forecast to grow 64.2% annually, significantly outpacing the South Korean market's 10.6% growth rate. Their R&D expenses highlight a strong commitment to innovation, with substantial investments driving their proprietary Hybrozyme™ Technology. The recent approval of Tergase® by Korea’s MFDS underscores this, showcasing a recombinant hyaluronidase with over 99% purity and lower immunogenicity compared to traditional animal-derived alternatives. Earnings are projected to surge by 99.46% per year, reflecting high growth potential in the biotech sector despite current unprofitability.

• Get an in-depth perspective on ALTEOGEN's performance by reading our health report here.

• Understand ALTEOGEN's track record by examining our Past report.

Celltrion (KOSE:A068270)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Celltrion, Inc., along with its subsidiaries, specializes in developing and producing protein-based drugs for oncology treatment in South Korea, with a market cap of ₩41.58 trillion.

Operations: Celltrion, Inc., along with its subsidiaries, generates revenue primarily from the production and sale of protein-based drugs for oncology treatment. The main revenue streams include Bio Medical Supply (₩3.54 trillion) and Chemical Drugs (₩507 billion).

Celltrion's revenue is expected to grow at 25.7% annually, significantly outpacing the South Korean market's 10.6% growth rate. Their earnings forecast of 59.8% per year indicates strong future potential despite a recent -40.4% decline in earnings over the past year. The company has invested heavily in R&D, with notable advancements like ZYMFENTRA® and SteQeyma®, enhancing their biosimilar portfolio and expanding patient access through agreements with Cigna Healthcare and Express Scripts, impacting 16.1 million insured lives.

• Delve into the full analysis health report here for a deeper understanding of Celltrion.

• Gain insights into Celltrion's past trends and performance with our Past report.

HYBE (KOSE:A352820)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: HYBE Co., Ltd. engages in music production, publishing, and artist development and management businesses with a market cap of ₩7.58 trillion.

Operations: HYBE Co., Ltd. generates revenue primarily from Label (₩1.28 billion), Platform (₩361.12 million), and Solution (₩1.24 billion) segments, with internal transactions accounting for -₩732.08 million. The company focuses on music production, publishing, and artist management to drive its business operations.

HYBE's revenue is forecast to grow at 14% annually, outpacing the South Korean market's 10.6%. Despite a one-off loss of ₩189.4B impacting recent results, earnings are projected to increase by 42.5% per year over the next three years, significantly higher than the market's 28.9%. The company has announced a share repurchase program for up to 150,000 shares, aimed at stock price stabilization. R&D expenses have been substantial in enhancing their digital content and artist management platforms.

• Click here and access our complete health analysis report to understand the dynamics of HYBE.

• Assess HYBE's past performance with our detailed historical performance reports.

Where To Now?

• Click here to access our complete index of 52 KRX High Growth Tech and AI Stocks.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com